See the DrugPatentWatch profile for ruxolitinib

Based on the information provided, I can tell you that Ruxolitinib is a medication that is formulated by Apotex. Ruxolitinib is a kinase inhibitor that is used to treat certain types of blood cancer and bone marrow disorders. However, the information provided does not specify what other drugs, if any, accompany Ruxolitinib in Apotex's formulation.

To find more information about this, I consulted DrugPatentWatch.com, a website that tracks drug patents and provides information about drug formulations. According to DrugPatentWatch.com, Ruxolitinib is the only active ingredient in Apotex's formulation. Therefore, based on the available information, it appears that there are no other drugs that accompany Ruxolitinib in Apotex's formulation.

It's worth noting that while Ruxolitinib may be formulated on its own, it is often used in combination with other drugs to treat certain conditions. For example, Ruxolitinib may be used in combination with corticosteroids to treat certain types of bone marrow disorders. However, these combinations are not specific to Apotex's formulation and would depend on the specific treatment plan prescribed by a healthcare provider.

In summary, based on the available information, there are no other drugs that accompany Ruxolitinib in Apotex's formulation. However, Ruxolitinib may be used in combination with other drugs depending on the specific treatment plan prescribed by a healthcare provider.

Sources:

* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/ruxolitinib)